| Layer | Description | Clinical Significance |
|---|---|---|
| Endoneurium | Surrounds individual nerve fibers | Must be intact for regeneration; contains blood-nerve barrier |
| Perineurium | Surrounds fascicles (bundles of fibers) | Main component of blood-nerve barrier; determines nerve tensile strength |
| Epineurium | Surrounds entire nerve | Contains vasa nervorum; surgical repair target |
| Feature | PNS (Schwann Cells) | CNS (Oligodendrocytes) |
|---|---|---|
| Cell:Axon ratio | 1 Schwann cell : 1 internode | 1 oligodendrocyte : up to 50 internodes |
| Regeneration | Good (Schwann cells guide regrowth) | Poor (inhibitory environment) |
| Diseases | GBS, CIDP, CMT | MS, leukodystrophies |
Saltatory conduction allows action potentials to “jump” between nodes of Ranvier, greatly increasing conduction velocity. Demyelination exposes paranodal K+ channels โ hyperpolarization โ conduction failure.
| Fiber Type | Diameter (ฮผm) | Velocity (m/s) | Myelination | Function |
|---|---|---|---|---|
| Aฮฑ | 12-20 | 70-120 | Heavy | Motor to skeletal muscle; proprioception (Ia, Ib) |
| Aฮฒ | 5-12 | 30-70 | Heavy | Touch, pressure (type II) |
| Aฮณ | 3-6 | 15-30 | Medium | Motor to muscle spindle (intrafusal) |
| Aฮด | 2-5 | 12-30 | Light | Fast pain, temperature, touch (type III) |
| B | 1-3 | 3-15 | Light | Preganglionic autonomic |
| C | 0.5-1.5 | 0.5-2 | Unmyelinated | Slow pain, temperature, postganglionic autonomic (type IV) |
Conduction velocity โ 6 ร diameter (in ฮผm). Large, myelinated fibers (Aฮฑ) are affected first by compression/ischemia. Small unmyelinated fibers (C) are affected first by metabolic/toxic neuropathies (diabetes).
| Fiber Type Affected | Clinical Features | Example Conditions |
|---|---|---|
| Large fiber | Loss of proprioception, vibration; sensory ataxia; areflexia | GBS, CIDP, B12 deficiency, Friedreich ataxia |
| Small fiber | Burning pain, loss of pinprick/temperature; autonomic dysfunction; preserved reflexes | Diabetic neuropathy (early), amyloid, Fabry disease |
| Motor fiber | Weakness, atrophy, fasciculations | ALS, MMN, lead toxicity |
| Autonomic fiber | Orthostatic hypotension, anhidrosis, GI/GU dysfunction | Diabetes, amyloid, autoimmune autonomic ganglionopathy |
Definition: EPP amplitude is normally 3-4x greater than threshold needed for muscle AP
Clinical significance:
P/Q-type Ca2+ channels are the target in Lambert-Eaton myasthenic syndrome. SNARE proteins (synaptobrevin, SNAP-25, syntaxin) are targeted by botulinum toxin and tetanus toxin.
| Feature | Myasthenia Gravis | Lambert-Eaton | Botulism |
|---|---|---|---|
| Target | Postsynaptic AChR | Presynaptic P/Q Ca2+ channels | Presynaptic SNARE proteins |
| Mechanism | Antibody blocks/destroys AChR | Antibody reduces Ca2+ influx โ less ACh release | Toxin cleaves SNAREs โ blocks ACh release |
| Weakness pattern | Ocular, bulbar, proximal; fatigable | Proximal legs > arms; improves with exercise | Descending: cranial โ limbs โ respiratory |
| Reflexes | Normal | Reduced/absent (improve post-exercise) | Reduced/absent |
| Autonomic | Usually spared | Dry mouth, constipation, impotence | Prominent (dilated pupils, dry mouth, ileus) |
| RNS pattern | Decrement at low-frequency (2-3 Hz) | Low baseline CMAP; increment >100% post-exercise | Low baseline CMAP; small increment post-exercise |
| Association | Thymoma (10-15%); thymic hyperplasia | Small cell lung cancer (50-60%) | Contaminated food, wound, infant (honey) |
Antibodies:
Clinical features:
Myasthenic crisis: Respiratory failure requiring intubation; triggered by infection, surgery, medications
Drugs that worsen MG: Aminoglycosides, fluoroquinolones, beta-blockers, magnesium, neuromuscular blockers
Key features:
Cancer association:
Treatment: 3,4-diaminopyridine (blocks K+ channels โ prolongs depolarization โ more Ca2+ entry)
MG = fatigable (gets worse with use). LEMS = facilitates (gets better with use). Both have proximal weakness. LEMS has autonomic symptoms; MG does not. Always screen LEMS for SCLC!
| Type | Pathology | Recovery | EMG/NCS |
|---|---|---|---|
| Neurapraxia | Local demyelination; axon intact | Complete; weeks to 3 months | Conduction block; no denervation |
| Axonotmesis | Axon disrupted; endoneurium intact | Good; 1 mm/day (1 inch/month) | Wallerian degeneration; fibs/PSWs; reinnervation potentials |
| Neurotmesis | Complete nerve transection | Poor; requires surgery | Complete denervation; no recovery without repair |
| Grade | Seddon Equivalent | Injury | Prognosis |
|---|---|---|---|
| I | Neurapraxia | Myelin only | Excellent |
| II | Axonotmesis | Axon (endoneurium intact) | Good |
| III | Axonotmesis | Axon + endoneurium | Variable |
| IV | Axonotmesis | Axon + endo + perineurium | Poor |
| V | Neurotmesis | Complete transection | None without surgery |
Neurapraxia = conduction block without Wallerian degeneration. No fibrillations on EMG. Full recovery expected. In axonotmesis, fibs/PSWs appear in 2-5 weeks (earliest in proximal muscles).
| Parameter | What It Measures | Abnormal In |
|---|---|---|
| Amplitude | Number of functioning axons | Axonal loss, conduction block |
| Conduction velocity | Speed of fastest fibers (myelination) | Demyelination |
| Distal latency | Time from distal stim to response | Distal demyelination |
| Feature | Demyelinating | Axonal |
|---|---|---|
| Conduction velocity | Markedly slow (<70% LLN) | Normal or mildly slow |
| Distal latency | Prolonged (>130% ULN) | Normal or mildly prolonged |
| Amplitude | May be preserved (early) or low | Low (proportional to axon loss) |
| Temporal dispersion | Present | Absent |
| Conduction block | Present | Absent |
| F-wave latency | Prolonged or absent | Normal or mildly prolonged |
| EMG fibrillations | Less prominent (unless secondary axonal loss) | Prominent |
| Examples | GBS (AIDP), CIDP, CMT1 | Diabetic neuropathy, AMAN, CMT2 |
Definition: >50% reduction in proximal vs distal CMAP amplitude (excluding common entrapment sites)
Significance:
Classic conditions:
Definition: Increased CMAP duration with proximal stimulation (>30% increase)
Mechanism: Different degrees of demyelination cause different conduction velocities โ desynchronization of impulses
Significance: Feature of acquired demyelinating neuropathies (not seen in uniform hereditary demyelination like CMT1A)
Conduction block = demyelinating. Low amplitudes everywhere = axonal. Temporal dispersion indicates acquired (non-uniform) demyelination. F-waves test proximal nerve segments not accessible to routine NCS.
| Disorder | Gene/Channel | Mechanism | Clinical Features |
|---|---|---|---|
| Hyperkalemic Periodic Paralysis | SCN4A (Nav1.4) | Gain of function โ prolonged depolarization | Attacks with high K+, fasting, rest after exercise; myotonia common |
| Paramyotonia Congenita | SCN4A (Nav1.4) | Impaired fast inactivation | Cold-induced myotonia; “paradoxical” myotonia (worsens with activity) |
| Sodium Channel Myotonia | SCN4A (Nav1.4) | Delayed inactivation | Myotonia without weakness; K+-aggravated |
| Disorder | Gene/Channel | Mechanism | Clinical Features |
|---|---|---|---|
| Hypokalemic Periodic Paralysis | CACNA1S (Cav1.1) – 70% SCN4A – 10% |
Loss of function โ reduced excitability | Attacks with low K+, carbs, rest after exercise; NO myotonia |
| Malignant Hyperthermia | RYR1 (ryanodine receptor) | Uncontrolled Ca2+ release from SR | Triggered by volatile anesthetics, succinylcholine; rigidity, hyperthermia, rhabdomyolysis |
| Disorder | Gene/Channel | Clinical Features |
|---|---|---|
| Myotonia Congenita (Thomsen/Becker) | CLCN1 (ClC-1) | Myotonia (muscle stiffness); improves with activity (“warm-up”); muscle hypertrophy; NO weakness |
| Feature | Hypokalemic PP | Hyperkalemic PP |
|---|---|---|
| K+ during attack | Low (<3.5) | High or normal |
| Triggers | Carbs, rest after exercise, stress | Fasting, rest after exercise, cold, K+ |
| Myotonia | Absent | Often present |
| Attack duration | Hours to days | Minutes to hours |
| Treatment | K+ replacement; acetazolamide prophylaxis | Carbs, inhaled ฮฒ-agonist; acetazolamide or dichlorphenamide prophylaxis |
HypoKPP: no myotonia. HyperKPP: myotonia common. Both worsen with rest after exercise. Acetazolamide works for both (metabolic acidosis โ reduced attack frequency). Malignant hyperthermia = RYR1 mutation; treat with dantrolene.
| Fiber | Function | Lost First In |
|---|---|---|
| Aฮฑ (large, myelinated) | Motor, proprioception | Compression, ischemia |
| Aฮฒ (large, myelinated) | Touch, pressure | Compression, ischemia |
| Aฮด (small, myelinated) | Fast pain, temperature | Metabolic (later) |
| C (small, unmyelinated) | Slow pain, autonomic | Metabolic (diabetes), toxic |
| Disorder | Low-Frequency RNS (2-3 Hz) | Post-Exercise/High-Frequency |
|---|---|---|
| Myasthenia Gravis | Decrement >10% | Repair of decrement (post-activation facilitation) |
| Lambert-Eaton | Low baseline; may decrement | Increment >100% |
| Botulism | Low baseline; may decrement | Small increment (20-40%) |
| Finding | Timing After Injury |
|---|---|
| Reduced recruitment | Immediately |
| Reduced SNAP/CMAP distal to lesion | 7-10 days (Wallerian degeneration complete) |
| Fibrillations in proximal muscles | 2-3 weeks |
| Fibrillations in distal muscles | 4-5 weeks |
| Nascent MUPs (reinnervation) | 2-4 months (depends on distance) |